Short Interest in Turnstone Biologics Corp. (NASDAQ:TSBX) Rises By 42.9%

Turnstone Biologics Corp. (NASDAQ:TSBX) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totalling 625,900 shares, an increase of 42.9% from the March 15th total of 438,000 shares. Approximately 4.7% of the company’s stock are sold short. Based on an average daily trading volume, of 181,300 shares, the days-to-cover ratio is currently 3.5 days.

Institutional Trading of Turnstone Biologics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Northern Trust Corp raised its holdings in shares of Turnstone Biologics by 12.6% in the fourth quarter. Northern Trust Corp now owns 65,072 shares of the company’s stock valued at $166,000 after purchasing an additional 7,290 shares during the last quarter. Citigroup Inc. acquired a new stake in shares of Turnstone Biologics in the third quarter valued at approximately $30,000. Rhumbline Advisers acquired a new stake in shares of Turnstone Biologics in the third quarter valued at approximately $31,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of Turnstone Biologics in the third quarter valued at approximately $60,000. Finally, New York State Common Retirement Fund acquired a new position in Turnstone Biologics during the third quarter worth $74,000. 52.51% of the stock is currently owned by institutional investors and hedge funds.

Turnstone Biologics Stock Performance

TSBX traded down $0.19 during trading on Friday, reaching $3.19. The company had a trading volume of 106,989 shares, compared to its average volume of 225,464. Turnstone Biologics has a 12 month low of $1.63 and a 12 month high of $13.20. The business’s fifty day moving average price is $3.12 and its 200 day moving average price is $2.78.

Turnstone Biologics (NASDAQ:TSBX) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.13. On average, analysts forecast that Turnstone Biologics will post -3.34 EPS for the current fiscal year.

About Turnstone Biologics

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas.